Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/37118

Target Organs and Levels of Evidence for TR-572

Toxicology and Carcinogenesis Studies of Methyl trans-Styryl Ketone (CASRN 1896-62-4) in F344/N Rats and B6C3F1 Mice (Feed and Dermal Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Methyl trans-styryl ketone
1896-62-4		 01/26/2011 Topical Application
R&M: 0, 10, 30, or 90 mg/kg; 50/sex/species/dose		 Southern Research Institute

Levels of Evidence

Male Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • Skin: Site of application, epidermis, hyperplasia; site of application, hyperkeratosis
Female Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • Skin: Site of application, epidermis, hyperplasia; site of application, hyperkeratosis
Male Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • Skin: Site of application, epidermis, hyperplasia; site of application, hyperkeratosis; site of application, inflammation, chronic; site of application, hyperplasia, melanocyte
Female Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • Skin: Site of application, epidermis, hyperplasia; site of application, hyperkeratosis; site of application, inflammation, chronic; site of application, hyperplasia, melanocyte